Results 11 to 20 of about 1,494 (190)

Metformin dual-targets metabolism and survival pathways in BPDCN [PDF]

iScience
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy with limited therapeutic options. Metformin, a commonly prescribed antidiabetic drug, has recently gained attention for its anticancer potential, but its effects on BPDCN remain unknown.
Mekkaoui, Zineb, Dal Zuffo, Ludivine, Vetter, Mathieu, Fredon, Maxime, Poussard, Margaux, Biichle, Sabeha, Mougey, Virginie, Mercier-Letondal, Patricia, Rolin, Gwenaël, Godet, Yann, Perruche, Sylvain, Garnache-Ottou, Francine, Saas, Philippe, Aribi, Mourad   +13 more
europepmc   +4 more sources

Venetoclax in the Therapeutic Strategy for BPDCN Management

eJHaem
Background Venetoclax, a B‐cell lymphoma 2 (BCL‐2) inhibitor, is a promising treatment for blastic plasmacytoid dendritic cell neoplasm (BPDCN) and is currently under evaluation in clinical trials.
Margaux Poussard, Maxime Fredon, Imane Belakri, Sabeha Biichle, Florian Renosi, Evan Seffar, Morgane Boichut, Romain Boidot, Elodie Bôle‐Richard, Francis Bonnefoy, Marie Kroemer, Sophie Bonnot‐Perrin, Philippe Saas, Olivier Adotévi, Francine Garnache‐Ottou, Fanny Angelot‐Delettre   +15 more
doaj   +5 more sources

Early detection of transformation to BPDCN in a patient with MDS [PDF]

Experimental Hematology & Oncology, 2018
Background Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy characterized by neoplastic cells that are positive for CD123, CD4, BDCA2, and TCL1 and aberrant expression of CD56.
Kamal Chamoun, Sanam Loghavi, Naveen Pemmaraju, Marina Konopleva, Michael Kroll, Madeleine Nguyen-Cao, Marisa Hornbaker, Courtney D. DiNardo, Tapan Kadia, Jeffrey Jorgensen, Michael Andreeff, Shimin Hu, Christopher B. Benton   +12 more
doaj   +4 more sources

Multi-organ single-cell analysis reveals PLD4 as a biomarker and potential therapeutic target of blastic plasmacytoid dendritic cell neoplasm [PDF]

Cancer Cell International
Background Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy originating from precursors of plasmacytoid dendritic cells.
Meng Wang, Xiaotong Xue, Zhenzhen Wang, Chuan Wang, Gongqi Yu, Zihao Mi, Xu Sang, Jianwen Wang, Yongxia Liu, Xuechao Chen, Shengli Chen, Guizhi Zhou, Hong Liu, Hao Chen, Yonghu Sun, Furen Zhang   +15 more
doaj   +3 more sources

t(8;14)(q24;q32) in BPDCN [PDF]

Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2019
Review on t(8;14)(q24;q32) in BPDCN, with data on ...
Huret, Jean-Loup
openaire   +4 more sources

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) [PDF]

Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2018
Review on Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), with data on clinics, and the genes involved.
Meloni-Ehrig, Aurelia
openaire   +4 more sources

Biallelic TET2 mutations and canonical ASXL1 mutations are frequent and cooccur in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): An institutional experience and review of literature

eJHaem, 2023
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is recurrently mutated in epigenetic pathway genes. We studied the myeloid‐related genetic mutations in a cohort of five patients with BPDCN and one paired relapse case at our institution and ...
Xi Zhang, Eric D. Hsi, Genevieve M. Crane, Yu‐Wei Cheng   +3 more
doaj   +2 more sources

Hyper-CVAD combined with Venetoclax for relapsed pediatric blastic plasmacytoid dendritic cell neoplasm (BPDCN): A case report and literature review. [PDF]

Leukemia Research Reports, 2022
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a very rare type of leukemia in children, Although BPDCN is a chemo-sensitive tumor, the relapse rate is very high.
Dima Abla, Miguel R. Abboud, Dolly Noun, Nidale Tarek, Naveen Pemmaraju   +4 more
doaj   +2 more sources

Impressive Skin and Systemic Response Despite Patient Underestimation and Delayed Diagnosis of Blastic Plasmacytoid Dendritic Cell Neoplasm. [PDF]

Case Rep Hematol
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy derived from precursors of plasmacytoid dendritic cells (pDCs), most frequently presenting with cutaneous involvement and often progressing to bone marrow (BM), lymph node, and central nervous system (CNS) infiltration.
Pacini E, Esposito Vangone B, Santoni A, Malchiodi M, Zuanelli Brambilla C, Sicuranza A, Beffa G, Bocchia M.   +7 more
europepmc   +2 more sources

Blastic Plasmacytoid Dendritic Cell Neoplasm in an Adolescent Managed in a Resource-Limited Setting: A Case Report. [PDF]

Case Rep Hematol
Blastic plasmacytoid dendritic cell neoplasms (BPDCNs) are rare, aggressive haematologic malignancies, uncommon in adolescents and often difficult to diagnose. We report a 16‐year‐old male presenting with lymphadenopathy, pancytopenia and constitutional symptoms.
Laudin G, Vaughan J, Pather S, Summers C, Maney A, Lakha A, Waja MF, Goqwana L, Hodkinson K.   +8 more
europepmc   +2 more sources